Louisiana Clinical Trials Report — June 2026

For Louisiana residents considering participation in clinical research, June 2026 presents a critical window of opportunity, with 49 trials across the state slated to close within the next 90 days. This means time is running out to enroll in these studies, including 7 that are actively seeking healthy volunteers. If you've been thinking about contributing to medical science, now is the moment to explore these options.

Individuals living with specific health conditions should also act quickly to investigate trials with impending deadlines. Research focusing on various conditions, from cancer to neurological disorders, has limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (2 trials)
• Agitation, psychomotor
• Atopic dermatitis
• Alzheimer disease
• ARDS (moderate or severe)
• Asthma
• AHRF
• Atrial fibrillation
• Atrial fibrillation (AF)
• Attention-deficit/hyperactivity disorder

New Horizons in Louisiana Research: June's Notable Trials

This month, Louisiana welcomes 21 new clinical trials, a significant increase from the 15 trials that opened in May 2026. These new studies contribute to the state's robust research landscape, which currently features 854 clinical trials actively recruiting across 53 cities and 657 research sites. Among the new additions are several substantial Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments and crucial vaccine development.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, a Phase 3 study titled "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This global trial aims to enroll 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron for weight management.
• Pfizer is leading two important Phase 3 vaccine trials for pneumococcal disease. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," seeks 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children and adolescents.
• For those with type 2 diabetes mellitus, AstraZeneca is sponsoring NCT07662109, a Phase 3 study investigating "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial plans for 2,000 participants to evaluate the combination therapy compared to individual treatments.
• Individuals experiencing migraines may be interested in two Phase 3 trials sponsored by Kallyope Inc.: NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," targeting 1,800 participants, and NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," which aims for 1,000 participants to assess long-term safety and tolerability.
• Beyond drug trials, two notable studies are focused on prenatal and obstetric conditions. BillionToOne Inc. is sponsoring NCT07643896, "The ADVANCE Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment," aiming for 1,000 participants. The University of North Carolina, Chapel Hill, is also leading NCT07661433, "Prospective Evaluation of an AI Diagnostic Ultrasound Tool for Fetal Weight Estimation," which seeks 1,000 pregnant individuals.

Diverse Conditions and Expanding Opportunities

The 21 new trials opening this month in Louisiana cover a diverse range of health conditions. The most common conditions addressed by these new studies include:

• Pneumococcal disease (2 trials)
• Obesity (2 trials)
• Overweight (2 trials)
• Type 2 diabetes mellitus (2 trials)
• Chronic pain (2 trials)
• Common warts (verruca vulgaris)
• Depression
• Disc herniation
• Down syndrome (trisomy 21)
• Fetal weight

In terms of intervention types, drug trials lead the way, accounting for 10 of the new studies. Other types of research include 5 trials categorized as "OTHER," 2 biological treatments, 1 behavioral intervention, and 1 diagnostic test.

Healthy Volunteers: A Vital Role in Research

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. As mentioned, 7 trials seeking healthy volunteers are closing soon, so prompt action is encouraged. Additionally, of the 21 new trials launched this month, 6 are actively seeking healthy volunteers. Statewide, a total of 87 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Geographic Reach: Research Spreading Across Louisiana

Louisiana's clinical research landscape continues to be robust, with trials available across 53 cities. This month, new research initiatives are concentrated in several key metropolitan areas, but opportunities are also expanding in other parts of the state. The cities with the most new trials include:

• New Orleans (6 new trials)
• Baton Rouge (4 new trials)
• Shreveport (4 new trials)
• Zachary (2 new trials)
• Chalmette (2 new trials)
• Covington (2 new trials)
• Marrero (1 new trial)
• Monroe (1 new trial)
• Lafayette (1 new trial)
• Jefferson (1 new trial)

This distribution ensures that residents in various regions of Louisiana have access to cutting-edge research, from the major urban centers to smaller communities.

Inclusive Participation: Who Can Join?

Clinical trials in Louisiana are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 5 include children as participants, and 18 include older adults, ensuring that research benefits diverse age groups. There are also 2 new trials specifically for female participants this month. Industry sponsors are driving significant research efforts, with 15 new trials sponsored by pharmaceutical companies such as AstraZeneca, Eli Lilly and Company, Kallyope Inc., and Pfizer. Academic institutions also play a vital role, with Louisiana State University Health Sciences Center Shreveport sponsoring 2 new trials.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Louisiana.